This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may slow down how quickly your liver processes your cancer medicine.
What might happen:
The amount of your cancer medicine in your blood may increase and cause more side effects than expected.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to perform certain laboratory tests more often while you are taking your medicines. Be sure to keep all of your laboratory appointments. Let your doctor know right away if you experience an irregular heartbeat, dizziness or fainting episodes; unusual tiredness, shortness of breath, paleness; unusual or unexplained bleeding or bruising; signs of infection such as fever, cough, flu-like symptoms; burning on urination; muscles aches; or worsening of skin problems.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Farydak (panobinostat) US prescribing information. Novartis Pharmaceuticals Corporation February, 2015.
2.Istodax (romidepsin) US prescribing information. Celgene Corporation June, 2013.
3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
4.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..